Malignancy in Patients With Inborn Errors of Immunity Beyond Infectious Complication: Single Center Experience for 30 Years
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Cancer incidence is known to be higher in patients with inborn errors of immunity (IEI) compared to the general population in addition to traditionally well-known infection susceptibility. We aimed to investigate cancer occurrence in patients with IEI in a single center. Methods: Medical records of IEI patients treated at Samsung Medical Center, Seoul, Korea were retrospectively reviewed from November 1994 to September 2023. Patients with IEI and cancer were identified. Results: Among 194 patients with IEI, seven patients (3.6%) were diagnosed with cancer. Five cases were lymphomas, 4 of which were Epstein-Barr virus (EBV)-associated lymphomas. The remaining cases included gastric cancer and multiple myeloma. The median age at cancer diagnosis was 18 years (range, 1–75 years). Among patients with cancer, underlying IEIs included X-linked lymphoproliferative disease-1 (XLP-1, n=3), activated phosphoinositide 3-kinase delta syndrome (APDS, n=2), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) haploinsufficiency (n=2). Seventy-five percent (3/4) of XLP-1 patients, 40.0% (2/5) of APDS patients, and 50.0% (2/4) of CTLA-4 haplo-insufficiency patients developed cancer. Patients with XLP-1 developed cancer at earlier age (median age 5 years) compared to those with APDS and CTLA-4 (P<0.001). One patient with APDS died during hematopoietic cell transplantation. Conclusions: Cancer occurred in 3.6% of IEI patients at a single center in Korea. In addition to infectious complications and inflammation, physicians caring for IEI patients should be aware of the potential risk of cancer, especially in association with EBV infection.
Abstract
Purpose: Cancer incidence is known to be higher in patients with inborn errors of immunity (IEI) compared to the general population in addition to traditionally well-known infection susceptibility. We aimed to investigate cancer occurrence in patients with IEI in a single center. Methods: Medical records of IEI patients treated at Samsung Medical Center, Seoul, Korea were retrospectively reviewed from November 1994 to September 2023. Patients with IEI and cancer were identified. Results: Among 194 patients with IEI, seven patients (3.6%) were diagnosed with cancer. Five cases were lymphomas, 4 of which were Epstein-Barr virus (EBV)-associated lymphomas. The remaining cases included gastric cancer and multiple myeloma. The median age at cancer diagnosis was 18 years (range, 1–75 years). Among patients with cancer, underlying IEIs included X-linked lymphoproliferative disease-1 (XLP-1, n=3), activated phosphoinositide 3-kinase delta syndrome (APDS, n=2), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) haploinsufficiency (n=2). Seventy-five percent (3/4) of XLP-1 patients, 40.0% (2/5) of APDS patients, and 50.0% (2/4) of CTLA-4 haplo-insufficiency patients developed cancer. Patients with XLP-1 developed cancer at earlier age (median age 5 years) compared to those with APDS and CTLA-4 (P<0.001). One patient with APDS died during hematopoietic cell transplantation. Conclusions: Cancer occurred in 3.6% of IEI patients at a single center in Korea. In addition to infectious complications and inflammation, physicians caring for IEI patients should be aware of the potential risk of cancer, especially in association with EBV infection.
참고문헌 (34)
- Bousfiha A, "The 2022 update of IUIS phenotypical classification for human inborn errors of immunity", J Clin Immunol, 42, pp.1508~1520 (2022)
- Abolhassani H, "Hallmarks of cancers : primary antibody deficiency versus other inborn errors of immunity", Front Immunol, 12, pp.720025~ (2021)
- Pai SY, "How immunodeficiency can lead to malignancy", Hematology(Am Soc Hematol Educ Program), 2021, pp.287~295 (2021)
- Gasser S, "DNA damage response and development of targeted cancer treatments", Ann Med, 39, pp.457~464 (2007)
- Mortaz E, "Cancers related to immunodeficiencies : update and perspectives", Front Immunol, 7, pp.365~ (2016)
- Tiri A, "Inborn errors of immunity and cancer", Biology(Basel), 10, pp.10~ (2021)
- Kwon WK, "Case report : novel splicing variant in SH2D1A in a patient with X-linked lymphoproliferative syndrome type 1", Front Pediatr, 10, pp.812590~ (2022)
- Filipovich AH, "Primary immunodeficiencies : genetic risk factors for lymphoma", Cancer Res, 52, pp.5465s~5467s (1992)[DOI]
- Mueller BU, "Cancer in children with primary or secondary immunodeficiencies", J Pediatr, 126, pp.1~10 (1995)
- Ioachim HL, "The opportunistic tumors of immune deficiency", Adv Cancer Res, 54, pp.301~317 (1990)
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2023", Cancer Research and Treatment, 55(2), pp.400~407 (2023), 대한암학회[DOI]
- "Cancer incidence rate by age group" (2023)[URL]
- Mayor PC, "Cancer in primary immunodeficiency diseases : cancer incidence in the United States Immune Deficiency Network Registry", J Allergy Clin Immunol, 141, pp.1028~1035 (2018)
- Salavoura K, "Development of cancer in patients with primary immunodeficiencies", Anticancer Res, 28, pp.1263~1269 (2008)
- Jiang Y, "The natural history of X-linked lymphoproliferative disease(XLP1) : lessons from a long-term survivor", Case Reports Immunol, 2020, pp.8841571~ (2020)
- Tangye SG, "XLP : clinical features and molecular etiology due to mutations in SH2D1A encoding SAP", J Clin Immunol, 34, pp.772~779 (2014)
- Purtilo DT, "Methods of detection of new families with X-linked lymphoproliferative disease", Cancer Genet Cytogenet, 51, pp.143~153 (1991)
- Panchal N, "X-linked lymphoproliferative disease type 1 : a clinical and molecular perspective", Front Immunol, 9, pp.666~ (2018)
- Tomomasa D, "Preemptive hematopoietic cell transplantation for asymptomatic patients with X-linked lymphoproliferative syndrome type 1", Clin Immunol, 237, pp.108993~ (2022)
- Thouenon R, "Activated PI3Kinase delta syndrome-a multifaceted disease", Front Pediatr, 9, pp.652405~ (2021)
- Singh A, "An updated review on activated PI3 kinase delta syndrome(APDS)", Genes Dis, 7, pp.67~74 (2019)
- Redenbaugh V, "Disorders related to PI3Kδ hyperactivation : characterizing the clinical and immunological features of activated PI3-kinase delta syndromes", Front Pediatr, 9, pp.702872~ (2021)
- Jamee M, "Clinical, immunological, and genetic features in patients with activated PI3Kδ syndrome(APDS) : a systematic review", Clin Rev Allergy Immunol, 59, pp.323~333 (2020)
- Coulter TI, "Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome : a large patient cohort study", J Allergy Clin Immunol, 139, pp.597~606 (2017)[DOI]
- Maccari ME, "Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome : the European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry", Front Immunol, 9, pp.543~ (2018)
- Wentink M, "Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections", Clin Immunol, 176, pp.77~86 (2017)
- Kuehn HS, "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4", Science, 345, pp.1623~1627 (2014)
- Schubert D, "Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations", Nat Med, 20, pp.1410~1416 (2014)
- Kucuk ZY, "CTLA-4 haploinsufficiency in a patient with an autoimmune lymphoproliferative disorder", J Allergy Clin Immunol, 140, pp.862~864.e4 (2017)[DOI]
- Egg D, "Therapeutic options for CTLA-4 insufficiency", J Allergy Clin Immunol, 149, pp.736~746 (2022)
- Egg D, "Increased risk for malignancies in 131 affected CTLA4 mutation carriers", Front Immunol, 9, pp.2012~ (2018)
- Bonilla FA, "International consensus document(ICON) : common variable immunodeficiency disorders", J Allergy Clin Immunol Pract, 4, pp.38~59 (2016)
- Chapel H, "Common variable immunodeficiency disorders : division into distinct clinical phenotypes", Blood, 112, pp.277~286 (2008)
- Mellemkjaer L, "Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives : a combined Danish and Swedish study", Clin Exp Immunol, 130, pp.495~500 (2002)